Alzheimer’s Market Analysis and Reports | Spain Conference Series

Market Analysis - Alzheimer’s 2020

Alzheimer’s Drugs Market by Drug Class (Cholinergic, Memantine, and Combined Drug) and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Sales): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017 - 2024”. According to the report, global Alzheimer’s Drugs Market was valued at approximately USD 3.64 billion in 2017 and is expected to generate revenue of around USD 5.66 billion by end of 2024, growing at a CAGR of around 8% between 2018 and 2024.

Alzheimer’s is a neurodegenerative progressive disease. Alzheimer's disease is a type of dementia which includes a broad group of brain diseases, such as problems with memory, thinking, and behavior for the long term. It is a type of dementia and near about 60-70% of Alzheimer's disease is the cause of dementia. Many researchers consider an increase in the level of protein amyloid in the brain is one of the causes of Alzheimer disease. Older age is the prominent cause of Alzheimer's, whereas there are also some genetic and some other causes of Alzheimer diseases. The exact cause of Alzheimer’s disease is still unknown.

Browse through 90 Tables & 12 Figures spread over 110 Pages and in-depth TOC on “Global Alzheimer’s Drugs Market Size & Share 2017: Industry Type, Growth, Segments Analysis and Forecast 2024”.

The global Alzheimer’s market is mainly driven by the growing occurrence of diseases in developed countries specifically in the Western region. Additionally, the prevalence of some neurodegenerative diseases such as dementia, growing occurrence of diseases, firm government encouragement for Alzheimer’s drug development, and growing alertness about the treatment of Alzheimer’s disease is resulting into increased demand for Alzheimer’s drugs market. However, high prices of the advance drugs may create restraints in underdeveloped countries. Also, awareness about Alzheimer’s disease in the developing regions remains restricted, which has resulted in unbalanced healthcare systems and obstructive research infrastructure. In Asia Pacific region, growing encouragement for mental care by governments is anticipated to drive the Alzheimer’s drugs market in the near future.

The report covers forecast and analysis for the Alzheimer’s drugs market on a global and regional level. The study provides historical data from 2015 along with a forecast from 2018 to 2024 based on revenue (USD Billion). The study includes drivers and restraints for the Alzheimer’s drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Alzheimer’s drugs market on a global level.

In order to give the users of this report a comprehensive view on the Alzheimer’s drugs market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses drug class, distribution channel, and regional segmentation are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the market on the global and regional basis.

This report segments the global Alzheimer’s drugs  market as follows:

 

Global Alzheimer’s Drugs: by Drug Class

Cholinergic

Memantine

Combined Drug

Global Alzheimer’s Drugs: by Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Sales

Global Alzheimer’s Drugs: by Region

North America

The U.S.

Europe

UK

France

Germany

Asia Pacific

China

Japan

India

Latin America

Brazil

The Middle East and Africa

We Welcome you for 15th World Summit on Alzheimer’s Disease, Dementia Care Research and Awareness on November 30-December 01, 2020- Barcelona, Spain

The Alzheimer’s disease is currently ranked as the sixth leading cause of death in the United States, but recent estimates indicate that the disorder may rank third, just behind heart disease and cancer, as a cause of death for older people.

Alzheimer’s is the most common cause of dementia among older adults. Dementia is the loss of cognitive functioning—thinking, remembering, and reasoning—and behavioral abilities to such an extent that it interferes with a person’s daily life and activities. Dementia ranges in severity from the mildest stage, when it is just beginning to affect a person’s functioning, to the most severe stage, when the person must depend completely on others for basic activities of daily living.

The causes of dementia can vary, depending on the types of brain changes that may be taking place. Other dementias include Lewy body dementia, frontotemporal disorders, and vascular dementia. It is common for people to have mixed dementia—a combination of two or more types of dementia. For example, some people have both Alzheimer’s disease and vascular dementia.